Valeant Pharma Q2 revenues climb

For the second quarter of 2011, the company has posted net income of $56.36m, or $0.17 per diluted share, compared to $33.97m, or $0.21 per diluted share, for the same period in 2010.

The company’s operating income for the second quarter of 2011 was $118.47m, compared to $48.81m for the same period in 2010.

For the six months ended 30 June 2011, the company reported total revenues of $1.17bn, compared to $458.41m for the same period in 2010.

Operating income was $193.21m for the six months of 2011, compared to $65.18m for the same period in 2010.

The company has reported net income of $62.84m for the six months of 2011, compared to $30.82m for the same period in 2010.